Low-dose adenoviral immunotherapy of rat hepatocellular carcinoma using single-chain interleukin-12

Human Gene Therapy

Volumn 16, Issue 3, 2005, Pages 307-317

  Waehler, Reinhard ^a   Ittrich, Harald ^a   Mueller, Lars ^a   Krupski, Gerrit ^a   Ameis, Detlev ^a,b   Schnieders, Frank ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b Evangelisches Krankenhaus Lutherhaus   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; INTERLEUKIN 12; PROTEIN SUBUNIT;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; DRUG ACTIVITY; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; LOW DRUG DOSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PROTEIN EXPRESSION; PROVOCATION TEST; RAT; SURVIVAL RATE; TUMOR VOLUME;

ADENOVIRIDAE; ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE THERAPY; GENETIC VECTORS; HISTOLOGICAL TECHNIQUES; IMMUNOTHERAPY; INTERLEUKIN-12; LIVER NEOPLASMS, EXPERIMENTAL; MAGNETIC RESONANCE IMAGING; MICE; RATS;

EID: 16344387497     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2005.16.307     Document Type: Article

References (42)

1. ADDISON, C.L., BRAMSON, J.L., HITT, M.M., MULLER, W.J., GAULDIE, J., and GRAHAM, F.L. (1998). Intratumoral coinjection of adenoviral vectors expressing IL-2 and IL-12 results in enhanced frequency of regression of injected and untreated distal tumors. Gene Ther. 5, 1400-1409.
2. ANDERSON, R., MACDONALD, I., CORBETT, T., HACKING G., LOWDELL, M.W., and PRENTICE, H.G. (1997). Construction and biological characterization of an interleukin-12 fusion protein (Flexi-12): Delivery to acute myeloid leukemic blasts using adeno-associated virus. Hum. Gene Ther. 8, 1125-1135.
3. ANDREWS, K.J., RIBAS, A., BUTTERFIELD, L.H., VOLLMER, C.M., EILBER, F.C., DISSETTE, V.B., NELSON, S.D., SHINTAKU, P., MEKHOUBAD, S., NAKAYAMA, T., TANIGUCHI, M., GLASPY, J.A., MCBRIDE, W.H., and ECONOMOU, J.S. (2000). Adenovirus-interleukin-12-mediated tumor regression in a murine hepatocellular carcinoma model is not dependent on CD1-restricted natural killer T cells. Cancer Res. 60, 6457-6464.
4. BARAJAS, M., MAZZOLINI, G., GENOVE, G., BILBAO, R., NARVAIZA, I., SCHMITZ, V., SANGRO, B., MELERO, I., QIAN, C., and PRIETO, J. (2001). Gene therapy of orthotopic hepatocellular carcinoma in rats using adenovirus coding for interleukin 12. Hepatology 33, 52-61.
5. BARR, D., TUBB, J., FERGUSON, D., SCARIA, A., LIEBER, A., WILSON, C., PERKINS, J., and KAY, M.A. (1995). Strain-related variations in adenovirally mediated transgene expression from mouse hepatocytes in vivo: Comparisons between immunocompetent and immunodeficient inbred strains. Gene Ther. 2, 151-155.
6. BEWIG, B., and SCHMIDT, W.E. (2000). Accelerated titering of adenoviruses. Biotechniques 28, 870-873.
7. BORMAN, A.M., LE MERCIER, P., GIRARD, M., and KEAN, K.M. (1997). Comparison of picornaviral IRES-driven internal initiation of translation in cultured cells of different origins. Nucleic Acids Res. 25, 925-932.
8. CAR, B.D., ENG, V.M., LIPMAN, J.M., and ANDERSON, T.D. (1999). The toxicology of interleukin-12: A review. Toxicol. Pathol. 27, 58-63.
9. CAVALLO, F., SIGNORELLI, P., GIOVARELLI, M., MUSIANI, P., MODESTI, A., BRUNDA, M.J., COLOMBO, M.P., and FORNI, G. (1997). Antitumor efficacy of adenocarcinoma cells engineered to produce interleukin 12 (IL-12) or other cytokines compared with exogenous IL-12. J. Natl. Cancer Inst. 89, 1049-1058.
10. COHEN, J. (1995). IL-12 deaths: Explanation and a puzzle. Science 270, 908.
11. COLOMBO, M.P., and TRINCHIERI, G. (2002). Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev. 13, 155-168.
12. DEMATTEO, R.P., MARKMANN, J.F., KOZARSKY, K.F., BARKER, C.F., and RAPER, S.E. (1996). Prolongation of adenoviral transgene expression in mouse liver by T lymphocyte subset depletion. Gene Ther. 3, 4-12.
13. ERNSTOFF, M.S., NAIR, S., BAHNSON, R.R., MIKETIC, L.M., BANNER, B., GOODING, W., DAY, R., WHITESIDE, T., HAKALA, T., and KIRKWOOD, J.M. (1990). A phase IA trial of sequential administration recombinant DNA-produced interferons: Combination recombinant interferon gamma and recombinant interferon alfa in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 8, 1637-1649.
14. FRITSCH, M., GEILEN, C.C., HEIDRICH, C., and REUTTER, W. (1995). Influence of extracellular matrices on ganglioside pattern of two hepatoma cell lines with different adhesive properties. FEBS Lett. 376, 159-163.
15. GOLAB, J., and ZAGOZDZON, R. (1999). Antitumor effects of interleukin-12 in pre-clinical and early clinical studies (Review). Int. J. Mol. Med. 3, 537-544.
16. GOLLOB, J.A., MIER, J.W., and ATKINS, M.B. (2001). Clinical use of systemic IL-12 therapy. Cancer Chemother. Biol. Response Modif. 19, 353-369.
17. HE, T.C., ZHOU, S., DA COSTA, L.T., YU, J., KINZLER, K.W., and VOGELSTEIN, B. (1998). A simplified system for generating recombinant adenoviruses. Proc. Natl. Acad. Sci. U.S.A. 95, 2509-2514.
18. KOBAYASHI, M., FITZ, L., RYAN, M., HEWICK, R.M., CLARK, S.C., CHAN, S., LOUDON, R., SHERMAN, F., PERUSSIA, B., and TRINCHTERI, G. (1989). Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J. Exp. Med. 170, 827-845.
19. KOZAK, M. (1987). An analysis of 5′-noncoding sequences from 699 vertebrate messenger RNAs. Nucleic Acids Res. 15, 8125-8148.
20. KRUPSKI, G., AMEIS, D., CATALDEGIRMEN, G., HERBST, H., HENSCHEL, M.G., NICOLAS, V., ROGIERS, X., and BUCHELER, E. (2001). [Native magnetic resonance tomography imaging of the Morris hepatoma (MH-7777A) in the rat]. Rofo. Fortschr. Geb. Rontgenstr. Neuen. Bildgeb. Verfahr. 173, 639-642.
21. LEONARD, J.P., SHERMAN, M.L., FISHER, G.L., BUCHANAN, L.J., LARSEN, G., ATKINS, M.B., SOSMAN, J.A., DUTCHER, J.P., VOGELZANG, N.J., and RYAN, J.L. (1997). Effects of single-dose interleukin-12 exposure on interleukin-12- associated toxicity and interferon-gamma production. Blood 90, 2541-2548.
22. LIESCHKE, G.J., RAO, P.K., GATELY, M.K., and MULLIGAN, R.C. (1997). Bioactive murine and human interleukin-12 fusion proteins which retain antitumor activity in vivo. Nat. Biotechnol. 15, 35-40.
23. LOSER, P., JENNINGS, G.S., STRAUSS, M., and SANDIG, V. (1998). Reactivation of the previously silenced cytomegalovirus major immediate-early promoter in the mouse liver: Involvement of NFkappaB. J. Virol. 72, 180-190.
24. MANETTI, R., PARRONCHI, P., GIUDIZI, M.G., PICCINNI, M.P., MAGGI, E., TRINCHIERI, G., and ROMAGNANI, S. (1993). Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells. J. Exp. Med. 177, 1199-1204.
25. MARTINET, O., DIVINO, C.M., ZANG, Y., GAN, Y., MANDELI, J., THUNG, S., PAN, P.Y., and CHEN, S.H. (2002). T cell activation with systemic agonistic antibody versus local 4-1BB ligand gene delivery combined with interleukin-12 eradicate liver metastases of breast cancer. Gene Ther. 9, 786-792.
26. MATTNER, F., FISCHER, S., GUCKES, S., JIN, S., KAULEN, H., SCHMITT, E., RUDE, E., and GERMANN, T. (1993). The interleukin-12 subunit p40 specifically inhibits effects of the interleukin-12 heterodimer. Eur. J. Immunol. 23, 2202-2208.
27. MAZZOLINI, G., QIAN, C., XIE, X., SUN, Y., LASARTE, J.J., DROZDZIK, M., and PRIETO, J. (1999). Regression of colon cancer and induction of antitumor immunity by intratumoral injection of adenovirus expressing interleukin-12. Cancer Gene Ther. 6, 514-522.
28. MELERO, I., MAZZOLINI, G., NARVAIZA, I., QIAN, C., CHEN, L., and PRIETO, J. (2001). IL-12 gene therapy for cancer: in synergy with other immunotherapies. Trends Immunol. 22, 113-115.
29. MORRIS, H.P., and MERANZE, D.R. (1974). Induction and some characteristics of "minimal deviation" and other transplantable rat hepatomas. Rec. Results Cancer Res. 44, 103-114.
30. NEUMEIER, R., DETHLEFS, U., and REUTTER, W. (1984). Different adhesion inhibiting activities of antisera against plasma membranes of liver and Morris hepatoma 7777. FEBS Lett. 168, 241-244.
31. OHNO, S., FUJII, T., UEDA, S., NAKAMOTO, T., KINUGASA, S., YOSHIMURA, H., TACHIBANA, M., KUBOTA, H., KUMAR DHAR, D., and NAGASUE, N. (2003). Predictive factors and timing for liver recurrence after curative resection of gastric carcinoma. Am. J. Surg. 185, 258-263.
32. PENNA, C., and NORDLINGER, B. (2002). Colorectal metastasis (liver and lung). Surg. Clin. North Am. 82, 1075-1090, x-xi.
33. PERTL, U., LUSTER, A.D., VARKI, N.M., HOMANN, D., GAEDICKE, G., REISFELD, R.A., and LODE, H.N. (2001). IFN-gamma-inducible protein-10 is essential for the generation of a protective tumor-specific CD8 T cell response induced by single-chain IL-12 gene therapy. J. Immunol. 166, 6944-6951.
34. PUTZER, B.M., RODICKER, F., HITT, M.M., STIEWE, T., and ESCHE, H. (2002). Improved treatment of pancreatic cancer by IL-12 and B7.1 costimulation: Antitumor efficacy and immunoregulation in a nonimmunogenic tumor model. Mol. Ther. 5, 405-412.
35. PUTZER, B.M., STIEWE, T., RODICKER, F., SCHILDGEN, O., RUHM, S., DIRSCH, O., FIEDLER, M., DAMEN, U., TENNANT, B., SCHERER, C., GRAHAM, F.L., and ROGGENDORF, M. (2001). Large nontransplanted hepatocellular carcinoma in wood-chucks: treatment with adenovirus-mediated delivery of interleukin 12/B7.1 genes. J. Natl. Cancer Inst. 93, 472-479.
36. SANGRO, B., MAZZOLINI, G., RUIZ, J., HERRAIZ, M., QUIROGA, J., HERRERO, I., BENITO, A., LARRACHE, J., PUEYO, J., SUBTIL, J.C., OLAGUE, C., SOLA, J., SADABA, B., LACASA, C., MELERO, I., QIAN, C., and PRIETO, J. (2004). Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors. J. Clin. Oncol. 22, 1389-1397.
37. SUNG, M.W., CHEN, S.H., THUNG, S.N., ZHANG, D.Y., HUANG, T.G., MANDELI, J.P., and WOO, S.L. (2002). Intratumoral delivery of adenovirus-mediated interleukin-12 gene in mice with metastatic cancer in the liver. Hum. Gene Ther. 13, 731-743.
38. TRINCHIERI, G. (1998a). Immunobiology of interleukin-12. Immunol. Res. 17, 269-278.
39. TRINCHIERI, G. (1998b). Interleukin-12: a cytokine at the interface of inflammation and immunity. Adv. Immunol. 70, 83-243.
40. TRINCHIERI, G., and SCOTT, P. (1999). Interleukin-12: Basic principles and clinical applications. Curr. Top. Microbiol. Immunol. 238, 57-78.
41. VENOOK, A.P. (1994). Treatment of hepatocellular carcinoma: Too many options? J. Clin. Oncol. 12, 1323-1334.
42. WANG, L., HERNANDEZ-ALCOCEBA, R., SHANKAR, V., ZABALA, M., KOCHANEK, S., SANGRO, B., KRAMER, M.G., PRIETO, J., and QIAN, C. (2004). Prolonged and inducible transgene expression in the liver using gutless adenovirus: A potential therapy for liver cancer. Gastroenterology 126, 278-289.